Moa Life Plus

Moa Life Plus EBIT Margin

The EBIT Margin (Operating Margin) of Moa Life Plus (142760.KQ) as of Oct 30, 2026 is -58.23 %. In the previous year, EBIT Margin (Operating Margin) was -53.26 % — a change of 9.33% (lower).

EBIT Margin

-58.23 %

YoY

9.33%

Last updated:

EBIT Margin (Operating Margin) of Moa Life Plus is 2025 -58.23 % . EBIT Margin (Operating Margin) of Moa Life Plus was 2024 -53.26 % . It decreases by 9.33% lower compared to the previous year.

Moa Life Plus's operating (EBIT) margin stands at -58.2%, down from -38.1% several years earlier.

The Moa Life Plus EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
-16.27 KRW
Jan 1, 2019
-56.04 KRW
Jan 1, 2020
-44.55 KRW
Jan 1, 2021
-38.09 KRW
Jan 1, 2022
-14.53 KRW
Jan 1, 2023
-31.94 KRW
Jan 1, 2024
-53.26 KRW
Jan 1, 2025
-58.23 KRW
The Moa Life Plus EBIT Margin history
YEAREBIT MarginYoY
-58.23 %+9.33%
-53.26 %+66.74%
-31.94 %+119.82%
-14.53 %-61.85%
-38.09 %-14.51%
-44.55 %-20.50%
-56.04 %+244.33%
-16.27 %-83.49%
-98.54 %-58.94%
-240.00 %-38.43%
-389.77 %+28.71%
-302.83 %+17,463.79%
-1.72 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Moa Life Plus Stock analysis

What does Moa Life Plus do? BL Corp. develops biopharmaceutical products and manufactures health functional foods and functional cosmetics. The company distributes Glu 100 Tablets, CellribonQ, and GentaQ to general hospitals and pharmacies. It generates revenue through the sale of these pharmaceuticals and health-related products to healthcare providers and retail outlets. The firm's product portfolio includes Glu 100 Tablets, CellribonQ, and GentaQ, which are distributed to general hospitals and pharmacies. These products are sold as part of the company's pharmaceutical and medical supplies distribution business. Revenue is derived from the sale of these branded medicines and health functional products. BL Corp. focuses on the distribution of specific branded pharmaceuticals and health functional products. The company's primary customers are general hospitals and pharmacies, which purchase Glu 100 Tablets, CellribonQ, and GentaQ for resale or direct use in healthcare settings. Moa Life Plus is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Moa Life Plus stock

EBIT Margin (Operating Margin) of Moa Life Plus is -58.23 % in 2025.

EBIT Margin (Operating Margin) of Moa Life Plus changed from -53.26 % to -58.23 %, representing a 9.33% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Moa Life Plus since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Moa Life Plus with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Moa Life Plus

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Moa Life Plus